Stock SIGY SIGN THERPAR
Add to a list
To use this feature you must be a member
Log inSign up

All News SIGN THERPAR

Equities

SIGY

US82674U2050

Market Closed - OTC Markets
Other stock markets
 12:27:32 2024-05-15 EDT 		5-day change 1st Jan Change
5.25 USD +5.00% Intraday chart for SIGN THERPAR +5.00% +10.99%
02-20 Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sigyn Therapeutics Reports First Quarter 2024 Financial Results
AQ
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
AQ
Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference
AQ
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sigyn Therapeutics Announces Reverse Stock Split
AQ
Sigyn Therapeutics Releases Letter to Shareholders
AQ
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer
CI
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
AQ
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
AQ
Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
AQ
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
AQ
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference
AQ
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
AQ
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
AQ
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application
CI
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SIGY Stock
  4. News SIGN THERPAR
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW